Experimental cell therapy tested in patients with Tough-to-Treat cancers
NCT ID NCT05237206
Summary
This first-in-human study tested the safety and early effectiveness of SUPLEXA, an experimental cell therapy, in adults with advanced cancers that had stopped responding to standard treatments. Forty-six participants with either metastatic solid tumors or blood cancers received weekly intravenous infusions of the therapy. The main goal was to understand how well patients tolerated the treatment and to look for any early signs that it might help control their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ONCOLOGY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Research Sa (Crsa)
Adelaide, South Australia, 5000, Australia
-
Greenslopes Private Hospital/Gallipoli Medical Research Foundation
Brisbane, Queeensland, 4120, Australia
-
Southern Oncology Clinical Research Unit (SOCRU)
Adelaide, South Australia, 5042, Australia
Conditions
Explore the condition pages connected to this study.